Difference between revisions of "ICRP Glossary"
Jump to navigation
Jump to search
| Line 511: | Line 511: | ||
*[[Fluoroscopically guided interventions]] | *[[Fluoroscopically guided interventions]] | ||
| + | |||
| + | *[[Fluoroscopically or computed tomography guided interventions]] | ||
*[[Forbiddenness]] | *[[Forbiddenness]] | ||
| Line 517: | Line 519: | ||
*[[Fractionation]] | *[[Fractionation]] | ||
| + | |||
| + | *[[Fractionation and dose delivery patterns]] | ||
*[[Fractionation sensitivity]] | *[[Fractionation sensitivity]] | ||
| + | |||
| + | *FSU (see [[Functional subunits]]) | ||
| + | |||
| + | *[[Functional subunits]] | ||
=== <big><span id="G">G</span></big> === | === <big><span id="G">G</span></big> === | ||
| Line 527: | Line 535: | ||
*[[Gastrointestinal syndrome]] | *[[Gastrointestinal syndrome]] | ||
| + | |||
| + | *[[Gastrulation]] | ||
| + | |||
| + | *[[Gastroschisis]] | ||
| + | |||
| + | *[[GATA binding protein 2]] | ||
| + | |||
| + | *GATA-2 (see [[GATA binding protein 2]]) | ||
*[[Genomic integrity]] | *[[Genomic integrity]] | ||
*[[Graded approach]] | *[[Graded approach]] | ||
| + | |||
| + | *[[Graft vs host disease]] | ||
*[[Granulocyte colony-stimulating factor]] | *[[Granulocyte colony-stimulating factor]] | ||
| Line 569: | Line 587: | ||
*[[Hormones]] | *[[Hormones]] | ||
| + | |||
| + | *[[Hounsfield unit]] | ||
*[[Human Alimentary Tract Model]] | *[[Human Alimentary Tract Model]] | ||
| Line 575: | Line 595: | ||
*[[Hyperbaric oxygen]] | *[[Hyperbaric oxygen]] | ||
| + | |||
| + | *[[Hyperfractionation]] | ||
*[[Hypertrophic cardiomyopathy]] | *[[Hypertrophic cardiomyopathy]] | ||
| Line 583: | Line 605: | ||
*[[Immune system]] | *[[Immune system]] | ||
| + | |||
| + | *IMRT (see [[Intensity-modulated radiotherapy]]) | ||
*[[In vivo radiobioassay]] | *[[In vivo radiobioassay]] | ||
| Line 609: | Line 633: | ||
*[[Institutional control]] | *[[Institutional control]] | ||
| + | |||
| + | *[[Intensity-modulated radiotherapy]] | ||
*[[Intake]] | *[[Intake]] | ||
| Line 675: | Line 701: | ||
*LLE (see [[Lifetime risk estimates]]) | *LLE (see [[Lifetime risk estimates]]) | ||
| + | |||
| + | *[[Local DRL]] | ||
*Loss of Life Expectancy (see [[Lifetime risk estimates]]) | *Loss of Life Expectancy (see [[Lifetime risk estimates]]) | ||
Revision as of 15:30, 28 March 2021
The ICRP Glossary collects ICRP’s definitive explanations of terms for current use. Some entries include historical descriptions to help readers better understand the term in a particular context.
It is a living document, updated regularly.
Many ICRP publications feature their own glossaries including, for example, highly specialized terms relevant to that specific publication or helpful for a reader to have close at hand, or when introducing new terms to be added to the ICRP Glossary.
Although the ICRP Glossary is not a dictionary, terms already well covered in the Oxford English Dictionary are not included here unless further explanation is needed to understand the way in which these terms are used in ICRP publications.
| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | ... |
A
- Acute radiation sickness (see Acute radiation syndrome)
- ALI (see Annual limit on intake)
- AMAD (see Activity median aerodynamic diameter)
- Ambient dose equivalent, H*(10)
- ARS (see Acute radiation syndrome)
B
- BAT (see Best available techniques)
- Bcr/abl (see Breakpoint cluster region/abelson)
C
- CACA (see Cobblestone area forming cell assay)
- CAFC (see Cobblestone area forming cell assay)
- CBCT (see Cone beam computed tomography)
- Cobblestone area cell assay (see Cobblestone area forming cell assay)
D
- DAC (see Derived air concentration)
- DD (see Doubling dose)
- DDI, detector dose indicator (see Exposure index)
- DIL (see Derived investigation level)
- DDREF (see Dose and dose-rate effectiveness factor)
- Detector dose indicator (see Exposure index)
- Directional dose equivalent H’(d,Ω)
- DLP (see Dose-length product)
- Dose (of ionising radiation)
- DQE (see Detector quantum efficiency)
- DRL (see Diagnostic reference level)
E
- EAR (see Excess absolute risk)
- EI (see Exposure index)
- ELR (i.e. Excess Lifetime Risk, see Lifetime risk estimates)
- Endosteal tissue (see Endosteum)
- ERR (see Excess relative risk)
- Excess lifetime risk (see Lifetime risk estimates)
F
- Fluence, Φ
- FSU (see Functional subunits)
G
- GATA-2 (see GATA binding protein 2)
- Gray (Gy)
H
- HATM (see Human Alimentary Tract Model]
I
- IMRT (see Intensity-modulated radiotherapy)
- Incidence rate (see Incidence)
J
K
- Kerma, K
L
- LET (see *Linear energy transfer)
- LLE (see Lifetime risk estimates)
- Loss of Life Expectancy (see Lifetime risk estimates)
- LSS (see Life Span Study)
M
- MMD (see *Mass median diameter)
N
- NHEJ (see Non-homologous end joining)
O
P
- Particle fluence (see Fluence)
- Personal dose equivalent, Hp(d)
- PLDR (see Potentially lethal damage repair)
Q
- Quality factor, Q(L)
R
- Radiation detriment (see Detriment)
- RAP (see Reference Animal and Plant)
- RBE (see Relative biological effectiveness)
- Reference female (see Reference Individual)
- Reference male (see Reference Individual)
- REID (see Lifetime risk estimates)
- Response function (see Dose-response function)
- Risk of exposure-induced death (see (see Lifetime risk estimates)
- ROS (see Reactive oxygen species)
- RR (see Relative risk)
S
- S coefficient (radiation weighted) SW[(rT←rs)]
- SAF (see Specific absorbed fraction)
- SEE (see Specific effective energy]
- Sievert (Sv)
- SLDR (see Sublethal damage repair)
- Source (see Radiation source)
T
- Transport of risk (see Transfer of risk)
U
V
W
- wT (see Tissue weighting factor)
- wR (see Radiation weighting factor)
X
Y
Z
...
- α/β ratio (see α/β value)
